SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    M.G. Rizzone, A. Fasano, A. Daniele, M. Zibetti, A. Merola, L. Rizzi, C. Piano, C. Piccininni, L.M. Romito, L. Lopiano, A. Albanese, Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?, Parkinsonism & Related Disorders, 2014, 20, 4, 376

    CrossRef

  2. 2
    Yi Liu, Weina Li, Changhong Tan, Xi Liu, Xin Wang, Yuejiang Gui, Lu Qin, Fen Deng, Changlin Hu, Lifen Chen, Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease, Journal of Neurosurgery, 2014, 121, 3, 709

    CrossRef

  3. 3
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, A. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment (part 1), Neurología (English Edition), 2013, 28, 8, 503

    CrossRef

  4. 4
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, A. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I), Neurología, 2013, 28, 8, 503

    CrossRef

  5. 5
    Carmen Rodriguez-Blazquez, Jose Manuel Rojo-Abuin, Mario Alvarez-Sanchez, Tomoko Arakaki, Alberto Bergareche-Yarza, Anabel Chade, Nelida Garretto, Oscar Gershanik, Monica M. Kurtis, Juan Carlos Martinez-Castrillo, Amelia Mendoza-Rodriguez, Henry P. Moore, Mayela Rodriguez-Violante, Carlos Singer, Barbara C. Tilley, Jing Huang, Glenn T. Stebbins, Christopher G. Goetz, Pablo Martinez-Martin, The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease, Parkinsonism & Related Disorders, 2013, 19, 10, 889

    CrossRef

  6. 6
    Anthony E. Lang, Eldad Melamed, Werner Poewe, Olivier Rascol, Trial designs used to study neuroprotective therapy in Parkinson's disease, Movement Disorders, 2013, 28, 1
  7. 7
    Tatjana Gazibara, Iva Stankovic, Aleksandra Tomic, Marina Svetel, Darija Kisic Tepavcevic, Vladimir S. Kostic, Tatjana Pekmezovic, Validation and cross-cultural adaptation of the Self-Assessment Disability Scale in patients with Parkinson’s disease in Serbia, Journal of Neurology, 2013, 260, 8, 1970

    CrossRef

  8. 8
    Jörg B. Schulz, Effects of selegiline and rasagiline on disease progression in Parkinson’s disease, Basal Ganglia, 2012, 2, 4, S41

    CrossRef

  9. 9
    Connie Marras, How will epidemiology shape our knowledge of the patterns of disease progression in Parkinson’s disease?, Basal Ganglia, 2012, 2, 4, 171

    CrossRef

  10. 10
    Alberto J Espay, Alfonso Fasano, Francesca Morgante, The six gaps in the search of neuroprotection for Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 2, 111

    CrossRef

  11. 11
    Katrina L. Paumier, Andrew D. Siderowf, Peggy Auinger, David Oakes, Lalitha Madhavan, Alberto J. Espay, Fredy J. Revilla, Timothy J. Collier, Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease, Movement Disorders, 2012, 27, 7
  12. 12
    Jonathan R. Evans, Sarah L. Mason, Roger A. Barker, Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I, 2012,

    CrossRef

  13. 13
    Olivier Rascol, Cheryl J Fitzer-Attas, Robert Hauser, Joseph Jankovic, Anthony Lang, J William Langston, Eldad Melamed, Werner Poewe, Fabrizio Stocchi, Eduardo Tolosa, Eli Eyal, Yoni M Weiss, C Warren Olanow, A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes, The Lancet Neurology, 2011, 10, 5, 415

    CrossRef

  14. 14
    Ping Liu, Tao Feng, Yong-jun Wang, Xuan Zhang, Biao Chen, Clinical heterogeneity in patients with early-stage Parkinson’s disease: a cluster analysis, Journal of Zhejiang University SCIENCE B, 2011, 12, 9, 694

    CrossRef

  15. 15
    Jonathan R Evans, Roger A Barker, Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease, Expert Opinion on Pharmacotherapy, 2011, 12, 8, 1249

    CrossRef

  16. 16
    David P. Breen, Andrew W. Michell, Roger A. Barker, Parkinson's disease – the continuing search for biomarkers, Clinical Chemistry and Laboratory Medicine, 2011, 49, 3

    CrossRef

  17. 17
    Weidong Pan, Shin Kwak, Yun Liu, Yan Sun, Zhenglong Fang, Baofeng Qin, Yoshiharu Yamamoto, Traditional Chinese Medicine Improves Activities of Daily Living in Parkinson's Disease, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  18. 18
    Walter Maetzler, Inga Liepelt, Daniela Berg, Progression of Parkinson's disease in the clinical phase: potential markers, The Lancet Neurology, 2009, 8, 12, 1158

    CrossRef